Agoracom Blog

VIDEO – Novamind $ Is Building the Infrastructure Required for a Regulated Psychedelics Industry $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 4:11 PM on Wednesday, February 17th, 2021

The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to 2027. 

As a consequence of the increasing incidence of mental health disorders, global demand for mental health facilities is increasing.

Psychedelics are going to go through parabolic, paradigm-shifting growth because of their ability to treat anxiety and depression amongst other things

Novamind is a leading mental health company specialized in psychedelic medicine, building the infrastructure required for a regulated psychedelics industry.


  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • 4 clinics in Utah, 1 more anticipated this quarter
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%)

Watch this powerful interview with Dr. Reid Robison, Chief Medical Officer and Director of Novamind.

Tags: , , , , ,

Comments are closed.